Focus Feature: COVID-19 vaccine protection and the immunocompromised
A booster dose of the Pfizer COVID-19 vaccine provides strong protection, roughly 80% in the first few months, against hospital admissions and emergency department visits caused by the delta and omicron variants. However, against omicron, this protection wanes over time for immunocompromised people — even after a third dose.
R&E News and Features
Cancer clinical trials at Kaiser Permanente
Clinical trials play a vital role in advancing cancer treatment at Kaiser Permanente, improving patients’ survival and quality of life.
Heart attacks increased in days after 2020 election
Hospitalizations for heart attack, stroke, and heart failure were 17% higher in the 5 days after the 2020 election than in the same 5 days 2 weeks before the election.
In the News
Niraparib showcases improved health-related QOL, reduced pain burden in mCRPC
Oncology Nursing NewsMay 5, 2022
Five questions...
for Dr. William Towner
Dr. William Towner is the regional physician director for the Division of Clinical Trials and leads the Clinician Investigator program for the Southern California Permanente Medical Group. In this Q&A he discusses how he became involved in clinical trials, highlights of his career, and how other physicians can be part of clinical research.